Patents Assigned to Senju Pharmaceuticals Co., Ltd.
-
Publication number: 20240180827Abstract: The present disclosure provides suspendable ophthalmic solutions with excellent redispersibility. The present disclosure provides an aqueous suspension agent comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant.Type: ApplicationFiled: March 29, 2022Publication date: June 6, 2024Applicants: SENJU PHARMACEUTICAL CO., LTD., MOCHIDA PHARMACEUTICAL CO., LTD.Inventor: Yuki YAMASHITA
-
Publication number: 20240132519Abstract: Compounds represented by formula (I), compounds of the less-polar group of two groups of diastereomers in which the carbon atom indicated by * in formula (II) is an asymmetric carbon atom, salts of the compounds, and solvates of the compounds or salts. The compounds have Nrf2 activating action.Type: ApplicationFiled: December 28, 2021Publication date: April 25, 2024Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Tomoyo MIYABE, Shinnosuke MACHIDA, Yuka OBA, Masaki KAKEHI, Takashi IMADA, Takeshi NAKAJIMA
-
Patent number: 11918630Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (?4?1?1), laminin 511 (?5?1?1), laminin 521 (?5?2?1), or fragments of these.Type: GrantFiled: October 30, 2015Date of Patent: March 5, 2024Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Patent number: 11857544Abstract: The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.Type: GrantFiled: December 13, 2018Date of Patent: January 2, 2024Assignees: THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Mayumi Yamamoto
-
Patent number: 11844776Abstract: The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): R4O—R5m??(IIa) wherein R4 is lower alkyl, R5 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.Type: GrantFiled: May 22, 2017Date of Patent: December 19, 2023Assignees: OSAKA CITY UNIVERSITY, SENJU PHARMACEUTICAL CO., LTD.Inventor: Shinji Hirotsune
-
Patent number: 11839618Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: October 9, 2015Date of Patent: December 12, 2023Assignees: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Publication number: 20230390235Abstract: The present invention aims to develop a method for treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, and provides an agent for preventing and/or treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, the agent comprising a specific compound.Type: ApplicationFiled: October 29, 2021Publication date: December 7, 2023Applicants: SENJU PHARMACEUTICAL CO., LTD., TOHOKU UNIVERSITYInventors: Mitsuyoshi AZUMA, Chiho FUKIAGE, Takashi IMADA, Yayoi KISHIMOTO, Noriyasu HIRASAWA, Yoshiro SAITO, Takashi TOYAMA
-
Publication number: 20230310402Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: ApplicationFiled: June 7, 2023Publication date: October 5, 2023Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Patent number: 11730722Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: GrantFiled: July 30, 2013Date of Patent: August 22, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Publication number: 20230210864Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Applicants: Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Publication number: 20230140127Abstract: Provided are a bodily fluid-collecting device that is capable of collecting a fixed amount of bodily fluid while minimizing damage to a living body, a method for collecting a bodily fluid using the device, and a method for collecting an aqueous humor using the device A bodily fluid-collecting device 1 comprises a needle part 2 having a needle tube 3 with a needle tip 32, and a capillary 5 removably connected to a base end part 33 of the needle tube 3 in its longitudinal direction on a side opposite to the needle tip 32.Type: ApplicationFiled: March 26, 2021Publication date: May 4, 2023Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Ryo YOSHINAGA, Tatsuya SAKAI
-
Patent number: 11633477Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.Type: GrantFiled: October 30, 2015Date of Patent: April 25, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Patent number: 11633404Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: October 9, 2015Date of Patent: April 25, 2023Assignees: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Publication number: 20230102590Abstract: The present disclosure provides the use of a polyether compound. In one embodiment, the present disclosure relates to improvement of the stability of a polyether compound that uses a polyether compound and improvement of the solubility of a sparingly soluble compound. In one embodiment, the present disclosure relates to a composition that includes a chelating compound, the composition being for stabilizing a polyether compound. In one embodiment, the present disclosure relates to a composition for improving the solubility of a sparingly soluble compound, the composition including at least one of a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound, by combining a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound. In one embodiment, regarding the present disclosure, regarding the polyether compound, the polyether compound includes a poloxamer and polyethylene glycol.Type: ApplicationFiled: February 2, 2021Publication date: March 30, 2023Applicant: Senju Pharmaceutical Co., Ltd.Inventor: Noriaki NISHIDA
-
Publication number: 20230024995Abstract: A compound having Nrf2-activating action is provided. The compound is represented by formula (I), a salt of the compound, or a solvate of the compound or salt: wherein R1a and R1b are identical or different and represent a hydrogen atom, an alkyl group, or a halogen atom; R2 represents an optionally substituted group derived from a heterocycle, and the heterocycle represents thiophene, furan, pyrrole, thiazole, or a fused ring including any of these heterocycles; R4 and R5 are identical or different and represent a hydrogen atom or an optionally substituted alkyl group, or R4 and R5 bind with each other to form —NH—CH—N—; R6 represents an optionally substituted alkyl group; A1, A2, A3, and A4 are identical or different and represent CH or N wherein the number of N is 1 or less; and Z represents a hydrogen atom or a halogen atom.Type: ApplicationFiled: July 3, 2020Publication date: January 26, 2023Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Tomoyo MIYABE, Shinnosuke MACHIDA, Yuka OBA
-
Publication number: 20220370404Abstract: This disclosure provides a means for treating dry eye. This disclosure can provide: a composition for use in treating dry eye; and a use thereof. The composition includes (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, a pharmaceutically acceptable salt thereof, or a solvate thereof. This disclosure can provide: a composition for treating dry eye; and a use thereof. The composition includes a Vi/Vc zone inhibitor.Type: ApplicationFiled: October 2, 2020Publication date: November 24, 2022Applicants: SENJU PHARMACEUTICAL CO., LTD., MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Takeshi TARUI, Shinya KOBAYASHI
-
Publication number: 20220296580Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.Type: ApplicationFiled: June 3, 2022Publication date: September 22, 2022Applicants: Kyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Patent number: 11439589Abstract: Provided are: emulsion eyedrops which have no concern with possible corneal injury induced by a nonionic surfactant, have excellent thermal stability and physical stability and can contain a sparingly water-soluble drug in an increased amount; and an emulsion eyedrops stabilization method. The emulsion eyedrops contain castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5. The emulsion eyedrops stabilization method is characterized by preparing emulsion eyedrops containing castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5.Type: GrantFiled: November 16, 2017Date of Patent: September 13, 2022Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Yasuhiro Mori
-
Publication number: 20220221473Abstract: The present disclosure provides a marker that shows a relationship with changes in the nerve density and morphology in the cornea. In one aspect, the present invention provides a marker for neuropathy in the eye, the expression of which changes in correlation with morphological parameters of the nerves in the eye. In some embodiments, the parameter may include at least one parameter selected from the group consisting of CNBD, CTBD, CNFD, CNFL, and tortuosity. In a particular embodiment, the parameter may include at least one parameter selected from CNBD and CTBD.Type: ApplicationFiled: April 24, 2020Publication date: July 14, 2022Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventor: Jun SHIMAZAKI
-
Patent number: 11382904Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.Type: GrantFiled: October 30, 2014Date of Patent: July 12, 2022Assignees: Kyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita